GlassScriptPhysician profile
April J Rozycki
NPI 1699009902
$2,062.57
in general payments reported to CMS, 2019-2025
19 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $391 · 2022: $367 · 2023: $561 · 2024: $328 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,150.78 |
| Education | $153.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $372.18 | 2021-2025 | Tremfya |
| Abbvie INC. | $334.28 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $203.48 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $181.63 | 2022-2023 | Sotyktu |
| Amgen INC. | $137.26 | 2021-2024 | Otezla |
| Incyte Corporation | $125.19 | 2021-2024 | Opzelura |
| Leo Pharma INC. | $114.07 | 2022-2025 | Adbry, Anzupgo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.00 | 2022 | |
| Ucb, INC. | $86.06 | 2021-2025 | Bimzelx |
| Genzyme Corporation | $75.21 | 2021-2024 | |
| Pfizer INC. | $69.76 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $50.55 | 2022-2023 | Libtayo |
| Galderma Laboratories, L.P. | $50.40 | 2022-2024 | Aklief |
| Arcutis Biotherapeutics, INC. | $49.41 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $36.28 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $36.28 | 2022-2023 | Puraply |
| Genentech USA, INC. | $15.77 | 2023 | Xolair |
| Stemline Therapeutics INC. | $12.94 | 2022 | |
| Dermavant Sciences, INC. | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Rozycki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.